ALKERMES | ALKS - Lucro Operacional

Preço das Ações
27.84
Mudança Diária
-0.16 -0.57%
Mensal
-15.38%
Anual
-19.00%
Q1 Previsão
26.93




Lucro Operacional Alterar Data
AbbVie USD 5.81B 1.23B 2025-12
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -45.43M 3.13M 2025-03
Eli Lilly USD 8.99B 599.9M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Heron Therapeutics USD 38K 3.83M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
J&J USD 5.59B 1.81B 2025-12
Malin Corporation EUR -1.1M 400K 2024-12
Merck USD 6.24B 318M 2025-12
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Otsuka Holdings JPY 67.25B 101.57B 2025-12
Ovoca Bio EUR -5.65M 3.45M 2022-06
Pfizer USD 4.65B 3.99B 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12